lunresertib
lunresertib: sourced relationships with 1 company · 3 clinical trials tracked.
lunresertib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could lunresertib → RPTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Repare Therapeutics Inc. (RPTX) | Phase 2 |
Clinical Trial Registry Records (3)
A Phase II Study of RP-6306 in Patients With Advanced Cancer
Primary endpoint: Response rate of RP-6306 in patients with selected cancers receiving standard agent
Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors
Primary endpoint: Safety and Tolerability of RP 6306 in Combination With FOLFIRI
Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)
Primary endpoint: Number of Patients With of Treatment-related Adverse Event Data Per CTCAE v5.0 Criteria to Determine Safety and Tolerability of RP-6306 in Combination With Gemcitabine.
Frequently asked questions
Which companies have sourced relationships with lunresertib?
lunresertib has dated SEC/FDA relationship records for Repare Therapeutics Inc..
How many clinical trials involve lunresertib?
BioSniper tracks 3 clinical trials involving lunresertib.